SNDX

$14.29+9.08%visit website

Syndax Pharmaceuticals Inc

Market Cap

$1.3B

Live price × Finnhub shares (2026-10-17)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.46

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

—

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	68,728	64,864	72,788	83,298	289,678
Research & development	78,641	58,845	68,036	67,481	273,003
Total operating expenses	131,276	99,066	112,783	125,193	468,318
Operating income	(62,548)	(34,202)	(39,995)	(41,895)	(178,640)
Interest expense	0.00	0.00	2.00	2.00	4.00
Income tax	433	0	0	0	433
Net income	(68,014)	(42,673)	(49,363)	(49,433)	(209,483)
EPS (basic) ($)		(0.48)	(0.55)	(0.55)	(2.37)
EPS (diluted) ($)		(0.48)	(0.55)	(0.55)	(2.37)
Weighted avg. shares (basic)		88,256	88,991	89,790
Weighted avg. shares (diluted)		88,256	88,991	89,790

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 2, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 43 more quarters, back to Mar 2015, with Tormere Pro.

Corporate Events (8-K)

10 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Nov 2, 2026 accepted 4:02 PM ET	2.02Earnings release5.02Officer / director change	Document SEC ↗
Aug 4, 2026 accepted 4:02 PM ET	2.02Earnings release	Document SEC ↗
Jul 14, 2026 accepted 8:30 AM ET	8.01Other events	Document SEC ↗
Jun 10, 2026 accepted 5:04 PM ET	1.01Material agreement2.03New debt obligation3.02Unregistered equity sale	Document SEC ↗
Jun 10, 2026 accepted 4:15 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
Jun 4, 2026 accepted 7:16 AM ET	1.01Material agreement2.03New debt obligation3.02Unregistered equity sale8.01Other events	Document SEC ↗
Apr 30, 2026 accepted 4:02 PM ET	2.02Earnings release	Document SEC ↗
Feb 26, 2026 accepted 4:02 PM ET	2.02Earnings release	Document SEC ↗
Jan 12, 2026 accepted 4:36 PM ET	2.02Earnings release7.01Reg FD disclosure	Document SEC ↗
Dec 19, 2025 accepted 4:30 PM ET	5.03Bylaws / fiscal year	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

41%

W/W +26.1pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

0.55x

Avg Daily Selling (90d)

88.9 sh/day

Baseline Daily Selling

390 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-29	2026-10-30	Podlesak Dennis	Director	Sale	8,000	$14.21	$114K	239.8K	View
2026-07-08	2026-07-09	Metzger Michael A	Director & Chief Executive Officer	Sale	32.4K	$24.24	$785K	484.8K	View
2026-06-12	2026-06-12	Botwood Nicholas A.J.	Head of R&D, CMO	Sale	31.2K	$18.14	$567K	60.9K	View
2026-06-11	2026-06-12	Botwood Nicholas A.J.	Head of R&D, CMO	Sale	34.3K	$18.00	$617K	60.9K	View
2026-02-09	2026-02-10	Metzger Michael A	Director & Chief Executive Officer	Sale	17.2K	$21.03	$361K	491.7K	View